Hangzhou Tigermed Consulting Co., Ltd (HKG:3347)

Market Cap	56.47B +33.1%
Revenue (ttm)	7.17B -3.5%
Net Income	669.02M -36.1%
EPS	0.78 -35.6%
Shares Out	n/a
PE Ratio	84.40
Forward PE	41.82
Dividend	0.32 (0.61%)
Ex-Dividend Date	Jun 12, 2025

Volume	2,144,000
Average Volume	2,396,744
Open	51.00
Previous Close	50.75
Day's Range	48.24 - 51.00
52-Week Range	22.30 - 60.60
Beta	0.82
RSI	45.73
Earnings Date	Mar 31, 2026

About HKG:3347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 10,251
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3347

Financial Performance

In 2024, HKG:3347's revenue was 6.60 billion, a decrease of -10.58% compared to the previous year's 7.38 billion. Earnings were 405.14 million, a decrease of -79.99%.

Financial numbers in CNY